|
Applying Evolving Targeted Therapy in Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-se... |